Personalized Therapy of Cardiovascular Diseases

  • Kewal K. Jain


The constantly growing volume of available data on cardiovascular disorders will require an organized interpretation of variations in DNA and mRNA as well as proteins, both on the individual and the population levels. A five-step strategy can be followed when trying to identify genes and gene products involved in differential responses to cardiovascular drugs (Siest et al. 2007): Pharmacokinetic-related genes and phenotypes Pharmacodynamic targets, genes, and products Cardiovascular diseases and risks depending on specific or large metabolic cycles Physiological variations of previously identified genes and proteins Environmental influences on them


Heart Attack Sudden Cardiac Death Isosorbide Dinitrate Target Cell Membrane SLCO1B1 Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Arking DE, Pfeufer A, Post W et al (2006) A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genetics 38:644–651CrossRefGoogle Scholar
  2. Caulfield M, Munroe P, Pembroke J et al (2003) Genome-wide mapping of human loci for essential hypertension. Lancet 361:2118–2123CrossRefPubMedGoogle Scholar
  3. Chasman DI, Posada D, Subrahmanyan L et al (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821–2827CrossRefPubMedGoogle Scholar
  4. Couvert P, Giral P, Dejager S et al (2008) Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9:1217–1227CrossRefPubMedGoogle Scholar
  5. Gage BF, Eby C, Milligan PE et al (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91:87–94PubMedGoogle Scholar
  6. Hakonarson H, Thorvaldsson S, Helgadottir A et al (2005) Effects of a 5-Lipoxygenase–Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction: A Randomized Trial. JAMA 293:2245–2256Google Scholar
  7. Johnson JA, Boerwinkle E, Zineh I et al (2009) Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 157:442–449CrossRefPubMedGoogle Scholar
  8. Judson R, Brain C, Dain B et al (2004) New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 177:345–351CrossRefPubMedGoogle Scholar
  9. Kathiresan S, Melander O, Anevski D et al (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358:1240–1249CrossRefPubMedGoogle Scholar
  10. Koenig W, Khuseyinova N, Lowel H et al (2004) Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110:1903–1908CrossRefPubMedGoogle Scholar
  11. Kunnas TA, Ilveskoski E, Niskakangas T et al (2002a) Association of the endothelial nitric oxide synthase gene polymorphism with risk of coronary artery disease and myocardial infarction in middle-aged men. J Mol Med 80:605–609CrossRefGoogle Scholar
  12. Kunnas TA, Lehtimaki T, Laaksonen R et al (2002b) Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study. J Mol Med 80:802–807CrossRefGoogle Scholar
  13. Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288–11293CrossRefPubMedGoogle Scholar
  14. Siest G, Marteau JB, Maumus S et al (2007) Pharmacogenomics and pharmacoproteomics: a strategy for cardio-vascular drugs. Ann Pharm Fr 65:203–210PubMedGoogle Scholar
  15. Taylor AL, Ziesche S, Yancy C et al (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. NEJM 351:2049–2057CrossRefPubMedGoogle Scholar
  16. Terra SG, Pauly DF, Lee CR et al (2005) Beta-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 77:127–137CrossRefPubMedGoogle Scholar
  17. Voora D, Shah SH, Reed CR et al (2008) Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circulation Cardiovasc Genet 1:100–106CrossRefGoogle Scholar
  18. Wickline SA, Neubauer AM, Winter P et al (2006) Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 26:435–441CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations